# Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/osimertinib-versus-platinum-pemetrexed-for-patients-with-egfr-t790m-advanced/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Vassiliki A. Papadimitrakopoulou,Tony Mok,Ji‐Youn Han,Myung‐Ju Ahn,Angelo Delmonte,Suresh S. Ramalingam,Seung‐Whan Kim,Frances A. Shepherd,Janessa Laskin,Yong He,Hiroaki Akamatsu,Willemijn S.M.E. Theelen,Wu‐Chou Su,Thomas John,Martin Sebastian,Helen Mann,Michele Miranda,Gianluca Laus,Yuri Rukazenkov,Yi‐Long Wu |
| Citations | 279 |
| DOI | 10.1016/j.annonc.2020.08.2100 |
| Fields | Medicine |
| Open Access | true |
| OA Status | hybrid |
| OA URL | https://doi.org/10.1016/j.annonc.2020.08.2100 |
| OpenAlex ID | https://openalex.org/W3082062836 |
| PMID | 32861806 |
| Type | article |
| Year | 2020 |

## Paper authors

- [Myung‐Ju Ahn](https://scholariq.org/researchers/myung-ju-ahn/)
- [Frances A. Shepherd](https://scholariq.org/researchers/frances-a-shepherd/)
- [Hiroaki Akamatsu](https://scholariq.org/researchers/hiroaki-akamatsu/)
- [Yi‐Long Wu](https://scholariq.org/researchers/yi-long-wu/)

## Paper journal

- [Annals of Oncology](https://scholariq.org/journals/annals-of-oncology/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.